A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Haemodialysis
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Paricalcitol (Primary)
- Indications Renal failure; Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Abbott Laboratories; AbbVie
- 10 Jun 2017 Biomarkers information updated
- 29 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.